393 / 1082
S378
ESTRO 36 2017
_______________________________________________________________________________________________
for items # 9, 17, 20, 22, and 26 (Figure 1). Finally, the
predictive power of the 10 IBDQ-B items with respect to
the acute worsening of the Bowel domain was investigated
by means of ROC analyses, setting the 25
th
percentile of
the Δ with respect to baseline (-1.10, Table 1) as end-
point. The IBDQ items # 1, 5, 13, 20 and 24 showed the
highest discriminative power (AUC >80%) in detecting
patients with acute IBDQ-B worsening.
Conclusion
Acute, patient-reported, IT from IM-WPRT is mild, but
some symptoms seem to persist one year after RT end.
Five out of ten questions of IBDQ-B were shown to be more
efficient in discriminating patients with larger acute
worsening of IBDQ-B.
PO-0728 BRCA2 mutation predicts poor survival in
prostate cancer: A compelling evidence from 8,988
patients.
M. Cui
1
, X.S. Gao
1
, X. Gu
1
, C. Peng
1
, X. Li
1
, M. Ma
1
1
Peking University First Hospital, Department of
Radiation Oncology, Beijing, China
Purpose or Objective
To focus on clinicopathological characteristics and
prognosis in men with prostate cancer (PCa) with Breast
Cancer 2 (BRCA2) mutation and offer some convincing
evidence for adding BRCA2 mutation as an early screening
biomarker into NCCN and EAU guidelines.
Material and Methods
We searched relevant articles from PubMed, Embase, Web
of Science and the Cochrane Library databases to evaluate
the overall survival (OS) and cancer-specific survival (CSS)
difference between BRCA2 mutation and non-carriers in
patients with prostate cancer. This meta-analysis was
performed following the (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) PRISMA Statement
guidelines strictly.
Results
We totally incorporated 525 BRCA2 mutations versus 8,463
non-carriers from 10 studies in our meta-analysis. The
results showed that BRCA2 mutation carriers was
correlated with worse CSS and OS than non-carriers, with
pooled Hazard Ratios (HRs) of 2.79 [95% confidence
interval (CI): 2.04-3.81, P<0.001] and 2.21 (95%CI: 1.61-
3.02, P<0.001) respectively. The results also
demonstrated that BRCA2 mutation carriers also harboring
higher Gleason Score(>7), TNM stage(>T3, N1, M1) and risk
level than non-carriers.
Conclusion
Our meta-analysis showed that BRCA2 mutation predicted
poor survival outcomes in patients with PCa. Therefore,
BRCA2 mutation as a helpful clinical prognostic factor
could stratify the high risk patients and provide clinical
strategies for more effective targeted treatments.
PO-0729 Normal Tissue Complication Probability for
late urinary toxicities after RT for prostate cancer
F. Palorini
1
, A. Cicchetti
1
, T. Rancati
1
, C. Cozzarini
2
, B.
Avuzzi
3
, C. Degli Esposti
4
, P. Franco
5
, E. Garibaldi
6
, G.
Girelli
7
, C. Iotti
8
, V. Vavassori
9
, R. Valdagni
10
, C. Fiorino
11
1
Fondazione IRCCS Istituto Nazionale dei Tumori,
Prostate Cancer Program, Milan, Italy
2
San Raffaele Scientific Institute, Radiotherapy, Milan,
Italy
3
Fondazione IRCCS Istituto Nazionale dei Tumori,
Radiation Oncology 1, Milan, Italy
4
Ospedale Bellaria, Radiotherapy, Bologna, Italy
5
Ospedale Regionale U. Parini-AUSL Valle d’Aosta,
Radiotherapy, Aosta, Italy
6
Istituto di Candiolo – Fondazione del Piemonte per
l’Oncologia IRCCS, Radiotherapy, Candiolo, Italy
7
Ospedale ASL9, Radiotherapy, Ivrea, Italy
8
Arcispedale S. M. Nuova – IRCCS, Radiotherapy, Reggio
Emilia, Italy
9
Cliniche Gavazzeni-Humanitas, Radiotherapy, Bergamo,
Italy
10
Fondazione IRCCS Istituto Nazionale dei Tumori,
Prostate Cancer Program- Radiation Oncology 1, Milan,
Italy